you would think that they would want to make an offer prior to the results becoming public this to pay less if the trial results are promising? They have much more initiate knowledge of trials results.
- Forums
- ASX - By Stock
- NEU
- Ann: Phase 3 enrolment successfully completed, results in Q4 2021
NEU
neuren pharmaceuticals limited
Add to My Watchlist
3.04%
!
$13.24

Ann: Phase 3 enrolment successfully completed, results in Q4 2021, page-38
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.24 |
Change
0.390(3.04%) |
Mkt cap ! $1.652B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $4.335M | 330.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 271 | $13.22 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.24 | 365 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 546 | 13.200 |
5 | 1092 | 13.190 |
4 | 448 | 13.180 |
5 | 1257 | 13.170 |
4 | 1295 | 13.160 |
Price($) | Vol. | No. |
---|---|---|
13.230 | 972 | 6 |
13.240 | 1147 | 10 |
13.250 | 1636 | 12 |
13.260 | 1721 | 9 |
13.270 | 1725 | 11 |
Last trade - 12.20pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online